SMITHKLINE BEECHAM DEFIES DOWNTURN FOR PHARMACEUTICAL STOCKS WITH 15% GAIN IN SECOND QUARTER; GENENTECH IS RUNNER-UP, WHILE 22 OUT OF 30 ISSUES FALL